Longitudinal immune kinetics of COVID-19 booster versus primary series vaccination: Insight into the annual vaccination strategy

Choi, Min Joo; Hyun, Hakjun; Heo, Jung Yeon; Seo, Yu Bin; Noh, Ji Yun; Cheong, Hee Jin; Kim, Woo Joo; Kim, Hwa Jung; Choi, Ju-yeon; Lee, Young Jae; Chung, Eun Joo; Kim, Su-Hwan; Jeong, Hyeonji; Kim, Byoungguk; Song, Joon Young

doi:10.1016/j.heliyon.2024.e27211

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-SARS-CoV-2 spike IgG levels then waned from 1 to 3 months after the third dose, but the rate of decline was substantially lower than what was detected after the primary series. These results are consistent with other studies [36,37].…”

Section: Discussionsupporting

confidence: 94%

Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination

Bullock,

Hickey,

Kemp

et al. 2024

Vaccines

View full text Add to dashboard Cite

SARS-CoV-2 vaccination-induced protection against infection is likely to be affected by functional antibody features. To understand the kinetics of antibody responses in healthy individuals after primary series and third vaccine doses, sera from the recipients of the two licensed SARS-CoV-2 mRNA vaccines were assessed for circulating anti-SARS-CoV-2 spike IgG levels and avidity for up to 6 months post-primary series and 9 months after the third dose. Following primary series vaccination, anti-SARS-CoV-2 spike IgG levels declined from months 1 to 6, while avidity increased through month 6, irrespective of the vaccine received. The third dose of either vaccine increased anti-SARS-CoV-2 spike IgG levels and avidity and appeared to enhance antibody level persistence—generating a slower rate of decline in the 3 months following the third dose compared to the decline seen after the primary series alone. The third dose of both vaccines induced significant avidity increases 1 month after vaccination compared to the avidity response 6 months post-primary series vaccination (p ≤ 0.001). A significant difference in avidity responses between the two vaccines was observed 6 months post-third dose, where the BNT162b2 recipients had higher antibody avidity levels compared to the mRNA-1273 recipients (p = 0.020).

show abstract

Section: Discussionsupporting

confidence: 94%